Brotzer, Lara
Nickler, Manuela
Kim, Min Jeong
Mueller, Beat
Blum, Claudine A.
Article History
Received: 14 June 2021
Accepted: 22 September 2021
First Online: 1 November 2021
Declarations
:
: Not applicable.
: Not applicable.
: CAB has received travel funding from Novo Nordisk and participated in an advisory board meeting for Tolvaptan for Otsuka Pharmaceutical Switzerland, in 2019. All other authors report no conflicts of interest.The results presented in this paper have not been published previously in whole or part.